BC
AXSM icon

Brookfield Corp’s Axsome Therapeutics AXSM Stock Holding History

Brookfield Corp’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-19,526
Closed -$1.4M – 150
2023
Q2 		$1.4M Sell
19,526
-12,074
-38% -$891K 0.01% 442
2023
Q1 		$1.95M Buy
31,600
+20,822
+193% +$1.37M 0.01% 423
2022
Q4 		$831K Buy
+10,778
New +$644K ﹤0.01% 516
2022
Q3 		– Sell
-64,846
Closed -$2.48M – 633
2022
Q2 		$2.48M Buy
+64,846
New +$2.05M 0.01% 372

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brookfield Corp's AXSM Position: Q3 2023 in Review

Brookfield Corp sold out of Axsome Therapeutics (AXSM) in Q3 2023, closing a stake of 19,526 shares — an estimated $1.4M sold.

Brookfield Corp first reported a position in AXSM in Q2 2022 and held it in 4 quarters. The position peaked at $2.48M in Q2 2022. 226 funds tracked by Wall St. Rank hold AXSM as of Q3 2023.

  • Brookfield Corp reported no remaining Axsome Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 19,526 Axsome Therapeutics shares in Q3 2023, an estimated $1.4M.
  • Brookfield Corp first reported a position in Axsome Therapeutics in Q2 2022 and held it in 4 quarters.
  • Brookfield Corp's Axsome Therapeutics position peaked at $2.48M in Q2 2022.
  • 226 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.